EC Number   |
General Information |
Reference |
|---|
    3.1.1.4 | evolution |
the enzyme harbors a consensus motif common to members of the GVIA-iPLA2 subfamily, the group VIA phospholipase A2 (GVIA-iPLA2) subfamily of enzymes functions independently of calcium within the cytoplasm of cells. The Caenorhabditis elegans genome encodes multiple putative GVIAiPLA2 isoforms |
729999 |
| 3.1.1.4 | malfunction |
absence of the GIVA PLA2 gene significantly reduces the effects of many inflammatory disease |
709421 |
| 3.1.1.4 | malfunction |
compared with the wild type, the plpA mutant exhibis reduced mortality, systemic infection, and inflammation in mice as well as low cytotoxicity toward the human epithelial INT-407 cells |
-, 751095 |
| 3.1.1.4 | malfunction |
inhibition of cPLA2 abolishes release of arachidonate but not palmitate from cells treated with fetal bovine serum. Inhibition of PLA2 precludes fetal bovine serum-stimulated formation of lipid droplets. Silenced expression of cPLA2 inhibits the formation of lipid droplets. Inhibition of cPLA2alpha under lipid droplets forming conditions alters endoplasmic reticulum structure |
708995 |
| 3.1.1.4 | malfunction |
inhibition of lp-PLA2 activity in conditioned medium by SB435495 or SB480848 significantly decreases lipid accumulation in macrophages |
708019 |
| 3.1.1.4 | malfunction |
knockdown of the enzyme in hepatitis C virus-infected cells or hepatitis C virus replicon-containing cells by small interfering RNA significantly suppresses hepatitis C virus replication and assembly, not the viral entry, overview. In addition, the chemical inhibitor methyl arachidonyl fluorophosphonate, which specifically inhibits phospholipase A2, reduces hepatitis C virus replication and assembly. The membranous web structure formation is defective |
730293 |
| 3.1.1.4 | malfunction |
lack of cPLA2alpha prolongs the G1 phase and reduces the proliferating capacity in response to mitogen stimulation without a significant change in the duration of the other phases of the cell cycle |
750503 |
| 3.1.1.4 | malfunction |
loss of cpla2a expression or inhibition of cpla2a activity diminishes G1 progression through the cell cycle |
750503 |
| 3.1.1.4 | malfunction |
mice deficient in secreted phospholipase A2 IIF are protected from epidermal hyperplasia in psoriasis, contact dermatitis, and skin cancer, where ethanolamine lysoplasmalogen is selectively reduced in the KO skin relative to wild-type skin |
751474 |
| 3.1.1.4 | malfunction |
patient with defects in GIVA PLA2 shows decreases in PLA2 activity, eicosanoid biosynthesis, and the generation of many small intestinal ulcers |
709421 |
